Methylprednisolone/Abiraterone acetate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Methylprednisolone/Abiraterone acetate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Methylprednisolone/Abiraterone acetate can convert its Small molecule drug profile and CYP17A1 x GR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Methylprednisolone/Abiraterone acetate (query alias: Methylprednisolone/Abiraterone acetate) |
|---|---|
| Modality / target | Small molecule drug; CYP17A1 x GR; CYP17A1 inhibitors, GR agonists |
| Highest global status | Approved |
| Originator | Sun Pharma ANZ Pty Ltd. |
| Active developers | Sun Pharma ANZ Pty Ltd. |
The MCP disease footprint includes Hormone-dependent prostate cancer, Metastatic castration-resistant prostate cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07703098 | Phase 4 | Not yet recruiting | 66 | Proportion of patients with recovery of the HPA axis. |
| NCT07650396 | Phase 3 | Recruiting | 276 | Change in disability and symptoms measured with the VISA-A questionnaire. |
| ChiCTR2600127755 | Not Applicable | Not yet recruiting | 53 | Treatment response rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
INDUCTION OF REMISSION THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM VASCULITIS: A SINGLE-CENTRE 40-YEAR EXPERIENCE
Not Applicable; n=216; evaluation: Positive. Reported fields: Long-term remission = Aspirin use was associated with higher rates of therapy discontinuation (p = 0.044) and long-term remission (p = 0.009), but not reduced relapse frequency. ; Long-term remission = Aspirin use was associated with higher rates of therapy discontinuation (p = 0.044) and long-term remission (p = 0.009), but not reduced relapse frequency.
EMULATED TARGET TRIAL OF CORTICOSTEROID PULSES FOR INDUCTION THERAPY IN ANCA-ASSOCIATED VASCULITIS
Not Applicable; n=234; evaluation: Negative. Reported fields: Composite outcome(death, end-stage renal disease, progression before remission, and minor or major relapse): HR = 1.71(95.0% CI, 0.76 - 3.85); Composite outcome(death, end-stage renal disease, progression before remission, and minor or major relapse): HR = 1.71(95.0% CI, 0.76 - 3.85)
Adjunctive Methylprednisolone After Thrombectomy: A Secondary Analysis Stratified by Admission White Blood Cell Count
Phase 4; n=1201; evaluation: Positive. Reported fields: death(90-day): aOR = 0.6(95.0% CI, 0.37 - 0.96); death(90-day): aOR = 0.6(95.0% CI, 0.37 - 0.96)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Methylprednisolone/Abiraterone acetate addresses Hormone-dependent prostate cancer, Metastatic castration-resistant prostate cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-03-23 | Fidia signed a binding agreement with sanofi for the acquisition of a sanofi portfolio of anti-inflammatory drugs | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
